Discussing the Supreme Court’s decision in Mayo v. Prometheus to reject two patents on a method for monitoring a patient’s blood to determine appropriate drug dosage as well as the decision’s potential to affect the profitability of personalized medicine, Partner Courtenay Brinckerhoff said the rejection is a disruption of the status quo that may result in less funding for research. First published in an article that appeared in Reuters, Ms. Brinckerhoff’s comments later appeared in additional publications including the Chicago Tribune, Yahoo! News, BioPortfolio and The Huffington Post.
People
Related News
July 11, 2025
In the News
David Morris Featured for Arrival to Foley's Salt Lake City Office
Foley & Lardner LLP partner David Morris is highlighted across legal press for his recent arrival to the firm.
July 10, 2025
In the News
Ann Marie Uetz Comments on Automotive Supply Chain Approach to Evolving Tariff Environment
Foley & Lardner LLP partner Ann Marie Uetz shared perspective from the automotive supply chain amid the evolving trade environment in the Crain's Detroit article, "Ford, Stellantis tighten terms on suppliers as tariff costs add up."
July 7, 2025
In the News
Louis Lehot Assesses Deal Trends in Shifting Market
Foley & Lardner LLP partner Louis Lehot assessed dealmaking trends in the Law360 article, "PE Dealmakers Best-Suited To Cut Through M&A Challenges."